The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

What is the current share price of Hyperion Global Growth Companies Fund (Managed Fund) (HYGG)? Hyperion Global Growth Companies Fund (Managed Fund)'s (HYGG) current share price is $6.89. This ...

RAHWAY, N.J. - Merck & Co., Inc., a global healthcare leader, has launched a Phase 3 clinical trial to evaluate the efficacy of its investigational drug MK-1084, a KRAS G12C... ByInvesting.com ...

In 2024, the FDA approved Merck's drug sotatercept-csrk (U.S. brand name: WINREVAIR, for injection, 45mg, 60mg) for treating adults with pulmonary arterial hypertension. This drug helps improve ...

Its blockbuster cancer drug, Keytruda, continues to be a significant growth driver, and the launch of Winrevair has further boosted revenues. While short-term volatility persists, Merck remains a ...

Aside from subcutaneous Keytruda, Merck is leaning on its pulmonary hypertension therapy Winrevair, which according to William Blair will be the pharma’s “main driver of growth,” expecting $4.9 ...

Moreover, the launch of Winrevair further bolstered revenue growth in 2024. The company’s Animal Health division also posted impressive results, achieving 13% sales growth in 2024. GreensKeeper ...

New Jersey’s life sciences community is celebrating another year of groundbreaking medical advancements from the scores of pharmaceutical companies headquartered across the state. As part of ...

The EY executive discusses trends in this sector and what he expects to see in the coming year.

Its Keytruda drug for cancer treatment is performing well, and the launch of Winrevair, a drug that treats pulmonary arterial hypertension (PAH), is also boosting revenue growth for the company.